BCRX (BioCryst Pharmaceuticals) Total Operating Expense: $1,247.7 Mil (TTM As of Mar. 2026)


BCRX BioCryst Pharmaceuticals Inc BCRX
66 GF Score
Price $9.65
GF Value $12.67
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioCryst Pharmaceuticals Total Operating Expense?

BioCryst Pharmaceuticals BCRX -3.40% 66 Total Operating Expense is $1,247.7 Mil as of Mar. 2026. GuruFocus rates BCRX with a GF Score™ of 66/100 and a GF Value™ of $12.67 (Modestly Undervalued). The stock has 4 warning signs investors should review.

BioCryst Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was $852.6 Mil. BioCryst Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $1,247.7 Mil.

BioCryst Pharmaceuticals Total Operating Expense Related Terms

BioCryst Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Total Operating Expense Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 327.63 412.67 430.64 440.99 514.77

BioCryst Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.74 130.77 127.62 136.65 852.63
BCRX
66GF Score
BioCryst Pharmaceuticals Inc BCRX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCryst Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,247.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $1,247.7 Mil mean?
BioCryst Pharmaceuticals (BCRX) has a Total Operating Expense of $1,247.7 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on BioCryst Pharmaceuticals and its competitors.
Is BioCryst Pharmaceuticals' Total Operating Expense too high?
BioCryst Pharmaceuticals' current Total Operating Expense is $1,247.7 Mil. Overall, BioCryst Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Total Operating Expense compare to SUPN and PBH?
BioCryst Pharmaceuticals' Total Operating Expense of $1,247.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on BioCryst Pharmaceuticals and its competitors. BioCryst Pharmaceuticals's current Total Operating Expense is $1,247.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.67, compared to a current price of $9.65 — trading 23.8% below its estimated fair value. The current Total Operating Expense is $1,247.7 Mil. BioCryst Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Total Operating Expense is $1,247.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $9.65 is trading 23.8% below its estimated GF Value™ of $12.67. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

  • Total Operating Expense: $1,247.7 Mil
  • GF Value™: $12.67 vs. price of $9.65 (23.8% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCryst Pharmaceuticals Business Description

Other Exchanges BCRX:MexicoBO1:Germany
Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
66GF Score

Get the complete analysis for BCRX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.65
Price
$12.67
GF Value